The first big corporate results comes today when the IT bellwether TCS and private banking major IndusInd Bank will showcase its July-September quarterly results. IndusInd Bank and TCS will set the tone not only for the respective sectors, but also for the key indices in the near term. 'Results' will be the keyword for the markets over the next few weeks or rather a month or a so from now.  At the time of writing, the SGX Nifty was trading almost 53 points below its yesterdays close at the level of 11,284.

Mahindra Susten, the renewable business arm of Mahindra and Mahindra (M&M) has formed a wholly owned subsidiary MSPL International DMCC in Dubai.

Diligent Media Corporation (DMCL) will stop the print edition of Daily News and Analysis (DNA) in Mumbai and Ahmedabad from October 10.

With the new outlets, total number of V-Mart Retail stores has increased to 243 stores in 186 cities across 19 states. 

The news is likely to have an adverse impact on the stocks of both the private sector bank and the mortgage financier.

The latest data by industry body, Association of Mutual Funds in India (AMFI) shows that asset under management (AUM) of the domestic mutual fund has declined by 3.8% month on month basis.

Polycab India Limited on Wednesday announced that the company has inaugurated Polycab Experience Centre at Shop No. 1, Sakharam Apartment, old Tapkir Galli, Pune.

Last week, Religare Enterprises announced that the company will conduct postal ballot to obtain approval of the shareholders of the company by the way of special resolution on disinvestment of entire investment of the company in material subsidiaries and Religare Housing Development Finance Corporation Limited and Sales, disposal and leasing of assets exceeding 20 per cent of assets of Religare Finvest Limited.

Usually, people use the words “need” and “want” interchangeably. However, they are way different from each other. Read on to find out more.

Zydus Cadila has received the final approval from the United States Federation of Drug Authority (USFDA) to market Colesevelam Hydrochloride Tablets, (US RLD - Welchol), 625 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.